daclizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4953	152923-56-3

Description:

Molecule	Description
Synonyms: zinbryta daclizumab zenapax	An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

zinbryta
daclizumab
zenapax

An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
5	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 26, 1999	EMA
Dec. 10, 1997	FDA	HOFFMAN-LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Transplant dysfunction	2399.88	47.75	405	4522	4341	56282799
Transplant rejection	1921.64	47.75	376	4551	9558	56277582
Ovarian cyst	1701.74	47.75	364	4563	14502	56272638
Acne	1590.24	47.75	367	4560	20769	56266371
Alopecia	789.86	47.75	418	4509	293040	55994100
Liver function test abnormal	403.59	47.75	151	4776	45520	56241620
Sleep disorder due to general medical condition, insomnia type	385.48	47.75	144	4783	43194	56243946
Multiple sclerosis relapse	268.31	47.75	112	4815	44791	56242349
Pneumonia	141.16	47.75	175	4752	406923	55880217
Condition aggravated	128.71	47.75	154	4773	344744	55942396
Loss of personal independence in daily activities	116.33	47.75	78	4849	81291	56205849
Rheumatoid arthritis	114.41	47.75	153	4774	382451	55904689
Incorrect route of product administration	93.93	47.75	43	4884	21286	56265854
Overdose	93.68	47.75	76	4851	105754	56181386
Kidney transplant rejection	85.09	47.75	26	4901	4187	56282953
Pain	75.34	47.75	173	4754	663011	55624129
Product use issue	59.29	47.75	77	4850	185964	56101176

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	149.70	37.74	36	530	12011	31684767

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Transplant dysfunction	2350.11	45.90	408	4658	6501	70916877
Ovarian cyst	1866.01	45.90	365	4701	11407	70911971
Transplant rejection	1753.79	45.90	373	4693	17798	70905580
Acne	1602.94	45.90	367	4699	24622	70898756
Alopecia	1020.29	45.90	416	4650	198074	70725304
Sleep disorder due to general medical condition, insomnia type	441.28	45.90	144	4922	35588	70887790
Liver function test abnormal	394.10	45.90	152	4914	60994	70862384
Multiple sclerosis relapse	305.90	45.90	115	4951	42902	70880476
Rheumatoid arthritis	172.57	45.90	152	4914	291653	70631725
Condition aggravated	132.17	45.90	157	4909	427478	70495900
Loss of personal independence in daily activities	127.81	45.90	78	4988	84832	70838546
Pneumonia	121.02	45.90	178	4888	596054	70327324
Pain	101.41	45.90	169	4897	628647	70294731
Incorrect route of product administration	93.37	45.90	43	5023	26449	70896929
Overdose	83.53	45.90	80	4986	169665	70753713
Product use issue	79.58	45.90	80	4986	179857	70743521
Drug ineffective	60.99	45.90	175	4891	939577	69983801
Encephalitis autoimmune	48.96	45.90	14	5052	2197	70921181

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA MoA	N0000010279	Interleukin 2 Receptor Antagonists
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
FDA MoA	N0000175621	Interleukin 2 Receptor-directed Antibody Interactions
FDA EPC	N0000175622	Interleukin-2 Receptor Blocking Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Renal transplant rejection	indication	236570004
Relapsing remitting multiple sclerosis	indication	426373005	DOID:2378

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-2 receptor	Membrane receptor	P01589 P14784 P31785	IL2RA_HUMAN IL2RB_HUMAN IL2RG_HUMAN	ANTIBODY BINDING	Kd	8		IUPHAR	DRUG LABEL

External reference:

ID	Source
D03639	KEGG_DRUG
4021083	VUID
N0000148541	NUI
4021083	VANDF
CHEMBL1201605	ChEMBL_ID
6880	IUPHAR_LIGAND_ID
DB00111	DRUGBANK_ID
CUJ2MVI71Y	UNII
1795335	RXNORM
11508	MMSL
241453	MMSL
4529	MMSL
d04262	MMSL
007284	NDDF
109133001	SNOMEDCT_US
386977009	SNOMEDCT_US
C0663182	UMLSCUI
D000077561	MESH_DESCRIPTOR_UI
7164	INN_ID

Pharmaceutical products:

None